Christian Kullmann, Evonik CEO

Evonik to make a mul­ti­mil­lion-dol­lar in­vest­ment at their In­di­ana site

While bas­ket­ball and mo­tor rac­ing may be king in In­di­ana, drug man­u­fac­tur­ing and APIs are mak­ing a run for the Hoosier state’s at­ten­tion.

On Thurs­day, Ger­man chem­i­cals com­pa­ny Evonik an­nounced plans to build a new, glob­al-scale pro­duc­tion fa­cil­i­ty for pro­duc­ing phar­ma­ceu­ti­cal lipids at their Tippeca­noe site in Lafayette, IN. The to­tal in­vest­ment for the site will amount to $220 mil­lion.

Ac­cord­ing to Evonik, the US gov­ern­ment is help­ing to fund the fa­cil­i­ty by pro­vid­ing up to $150 mil­lion through BAR­DA. Ad­di­tion­al sup­port will al­so be pro­vid­ed by the In­di­ana Eco­nom­ic De­vel­op­ment Cor­po­ra­tion, Greater Lafayette Com­merce and Duke En­er­gy. Con­struc­tion will be set to be­gin in ear­ly 2023, with the plant be­ing sched­uled to go live in 2025. The in­vest­ment al­so plans to cre­ate more than 80 jobs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.